Amneal Pharmaceuticals (AMRX) Barclays 27th Annual Global Healthcare Conference 2025 summary

Business performance and outlook

• Achieved strong growth in 2024 across all business segments, with momentum expected to continue through 2025 and mapped growth plans extending seven years ahead.

• Affordable medicine segment, including generics, biosimilars, and injectables, is positioned for significant expansion due to upcoming loss of exclusivity (LOE) events and government support for biosimilars.

• Specialty segment outperformed expectations, driven by the success of Crexont, with positive patient outcomes and rapid market uptake.

• Distribution segment exceeded expectations, leveraging US manufacturing advantages and strong government partnerships.

• International expansion is underway through partnerships in the Middle East, Southeast Asia, Canada, and Europe, with a direct sales approach in India targeting branded specialty assets.

Product pipeline and launches

• Launches 20-30 products annually in the affordable segment, with a robust pipeline and reduced price erosion in generics.

• Crexont is rapidly gaining market share, targeting over 1,000 prescriptions per week and aiming for more than 50% payer coverage by year-end.

• DHE auto-injector for migraine and cluster headache patients is expected to launch in the second half of 2025, with strong KOL support and additional sales force planned.

• Biosimilar pipeline includes launches of Xolair, Xgeva, Prolia, and OBI by 2027, with plans to integrate R&D and manufacturing for greater control and expansion.

• Partnership with Metsera focuses on peptide manufacturing, with new capacity coming online by 2027 and revenue contributions expected from 2028 onward.

Commercial strategy and market positioning

• Specialty business is expanding to general neurologists and long-term care, with Crexont expected to capture over 20% of the Parkinson’s market.

• Biosimilars are seen as entering a 'golden era,' with lower competition and favorable regulatory environment, aiming for top-five global position.

• Complex generics and injectables benefit from targeted capacity investments and a healthy market with many upcoming LOEs.

• International strategy leverages partnerships for distribution, with a focus on branded specialty products in emerging markets.

• Operating margins are expected to expand significantly over the next five years as higher-margin specialty and biosimilar products grow and fixed investments yield incremental returns.